Baxter

Spectral Medical Announces Fourth Quarter and Fiscal 2023 Results and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024
Emory Healthcare, Sepsis, Conference, SAMI, Motivation, Clinical professor, Partnership, Patient, EAA, Mayo Clinic, Mortality, Septic shock, EDEN, University, Spectral, Intensive care unit, Critical care, PMX, AME Publishing Company, TSX, Clinical trial, Nephrology, ICU, FDA, UCLA, Baxter, Marketing, Economics, Hemoperfusion, Pharmaceutical industry

TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023 and provided a corporate update.
  • Dr. John Kellum, Chief Medical Officer of Spectral Medical, stated, “We have witnessed robust enrollment activity to start 2024.
  • addition of two new trial sites in the fourth quarter – the Mayo Clinic and Emory Healthcare.
  • The Company concluded the 2023 year with cash of $2,952,000 compared to $8,414,000 cash on hand as of December 31, 2022.

Pharmacy Automation: Technologies and Global Markets Report 2024-2028 Featuring Major Players - BD, Baxter, Omnicell, and KUKA - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 3, 2024
Health, Pharmaceutical, RFID, Automation, Omnicell, Drug discovery, Internet of things, KUKA, ESG, Pharmacy, Internet, Artificial intelligence, Pharmacist, Workflow, Cloud computing, Growth, USD, Baxter, Approximation error

The "Pharmacy Automation: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmacy Automation: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The Global Pharmacy Automation Market was valued at USD 7.8 Billion in 2023, and is expected to reach USD 12.7 Billion by 2028, rising at a CAGR of 10.20%.
  • This report is designed to be a helpful business tool that will provide a thorough evaluation of the global pharmacy automation market.
  • Definitive and detailed estimates and forecasts of the global market are provided, followed by a detailed analysis of segments and regions.

Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy

Retrieved on: 
Monday, April 1, 2024
Technology, Medical Devices, Hospitals, FDA, Health Technology, Software, Biotechnology, General Health, Pharmaceutical, Health, SYR, Novum, LVP, EMR, Patient, State, Food and Drug Administration, CQI, Hospital, Pharmacist, Baxter International, Computer security, Safety, Nursing, Baxter, Medicine, Pump, Food, Medical device

Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software.
  • Offering the Novum IQ LVP in the U.S. demonstrates Baxter’s commitment to continued innovation in advancing infusion therapy.
  • “The Novum IQ platform represents a meaningful shift in how connected and intelligent infusion therapy can impact the way clinicians provide care.
  • IQ Enterprise Connectivity Suite, a scalable all-in-one server, integration engine and software application platform, designed to simplify infusion system connectivity for the Novum IQ Infusion Platform.

Baxter to Host Annual Meeting of Stockholders in Virtual Format

Retrieved on: 
Wednesday, March 27, 2024
Health Technology, Health, Medical Supplies, Online, Medtech, Central Time, Baxter International, Baxter, Annual general meeting, Holding company

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2024 Annual Meeting) in a virtual format on Tuesday, May 7, 2024 at 9 a.m., Central Time, as disclosed in Baxter’s proxy statement for the 2024 Annual Meeting.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2024 Annual Meeting) in a virtual format on Tuesday, May 7, 2024 at 9 a.m., Central Time, as disclosed in Baxter’s proxy statement for the 2024 Annual Meeting.
  • As always, whether or not a stockholder plans to attend the virtual 2024 Annual Meeting, all stockholders of record are encouraged to vote their shares prior to the 2024 Annual Meeting by one of the methods described in the proxy materials for the 2024 Annual Meeting.
  • A list of Baxter's stockholders of record will be available for examination by stockholders on the 2024 Annual Meeting website during the meeting.
  • Stockholders that have not voted their shares prior to the 2024 Annual Meeting will be able to vote their shares electronically at the 2024 Annual Meeting by clicking “Vote Here” on the meeting website.

Spectral Medical Announces Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation

Retrieved on: 
Wednesday, February 21, 2024
Baxter International, PMX, Sepsis, Intensive care unit, Amend, Investment, FDA, TSX, U.S. FDA, Risk, Baxter, Patient, Septic shock, United, Partnership, Pharmaceutical industry

TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to announce an extension to its supply and distribution agreement (the “Amended Agreement”) with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc. (“Baxter”) (NYSE: BAX), originally entered into in February 2020.

Key Points: 
  • TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to announce an extension to its supply and distribution agreement (the “Amended Agreement”) with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc. (“Baxter”) (NYSE: BAX), originally entered into in February 2020.
  • Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”).
  • “Baxter’s continued commitment to Spectral as our exclusive supply and distribution partner being extended for a ten-year period upon U.S. FDA approval provides us with great confidence in our commercialization path,” said Chris Seto, CEO of Spectral Medical.
  • On February 15, 2024, Spectral announced that it had reached the 90-patient enrollment threshold and provided written notification to Baxter of this achievement.

Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients

Retrieved on: 
Thursday, February 15, 2024
Baxter International, PMX, Sepsis, Intensive care unit, Spectral, FDA, TSX, Baxter, Patient, Septic shock, Acceleration, United, Partnership, Pharmaceutical industry

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a major milestone by reaching its Interim Enrollment target of patient 90 in its TIGRIS trial.

Key Points: 
  • TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a major milestone by reaching its Interim Enrollment target of patient 90 in its TIGRIS trial.
  • Under the terms of the Company’s Exclusive Distribution Agreement with Baxter International (“Baxter”) (NYSE:BAX), at Interim Enrollment, Baxter has the option to make a second milestone payment to Spectral to maintain its PMX exclusive distribution rights.
  • As such, Spectral has formally notified Baxter of reaching its Interim Enrollment target of 90 patients.
  • “Enrolling patient 90 represents a major milestone in many ways for Spectral as we continue to see acceleration across our Tigris trial sites and building confidence and momentum towards completing the trial,” said Chris Seto, CEO of Spectral Medical.

Starbreeze AB (publ) Year-end report 2023

Retrieved on: 
Thursday, February 15, 2024
Annual general meeting, Game, PAYDAY 2, IPS, DLC, Steam, Baxter, Early access, Fortnite, Policy, Heart, Starbreeze Studios, Depreciation, Video game

In line with the company's dividend policy, the Board of Directors proposes that no dividend is paid for the 2023 financial year.

Key Points: 
  • In line with the company's dividend policy, the Board of Directors proposes that no dividend is paid for the 2023 financial year.
  • December 4, Starbreeze announced that it had licensed the world's greatest role-playing game - Dungeons & Dragons® for Project Baxter.
  • January 17, Starbreeze announced the Early Access launch of The Tribe Must Survive on Steam on February 22, 2024.
  • As a company, Starbreeze stands strong, with a strong cash position and a balance sheet largely free of debt.

CTS Corporation Announces Appointment of Amy M. Dodrill to its Board of Directors

Retrieved on: 
Thursday, February 8, 2024
Baxter, Connect, CTS, Growth, Hill-Rom, Procept

Ms. Dodrill comes to CTS with over 25 years of experience in medical and technology companies and a proven track record of successfully leading and profitably growing global businesses serving key end markets.

Key Points: 
  • Ms. Dodrill comes to CTS with over 25 years of experience in medical and technology companies and a proven track record of successfully leading and profitably growing global businesses serving key end markets.
  • In that role, Ms. Dodrill successfully integrated two former Hillrom business units into Baxter.
  • Ms. Dodrill is a member of the board of directors of Procept BioRobotics (NASDAQ: PRCT), a commercial stage surgical robotics company, serving on the audit and compensation committees.
  • "CTS is pleased to welcome Amy Dodrill to the CTS board.

Tent México, A Coalition of 46 Companies, Launches With Shared Commitment to Connect Refugees and Migrants to Jobs in Mexico

Retrieved on: 
Wednesday, February 7, 2024
Partnership, SAP, PayPal, International Organization (journal), Research, HP Inc., Dow Chemical Company, WeWork, The Adecco Group, Walmart, Arca Continental, Accor, IOM, Workforce, ISS, HSBC, COPARMEX, Microsoft, Employment, Chobani, Accenture, FEMSA, Comex, Marriott International, John Menzies, LEAR, AT&T, Baxter, Face, Drug

Tent México is Tent's first national coalition to launch in Latin America, adding to existing coalitions in Canada, France, Spain and the United States.

Key Points: 
  • Tent México is Tent's first national coalition to launch in Latin America, adding to existing coalitions in Canada, France, Spain and the United States.
  • * Only 7% of respondents in Mexico reported being less likely to buy from companies hiring refugees.
  • Tent México will provide a range of free services to companies that will support their efforts to connect refugees and migrants, of all backgrounds, to work.
  • We look forward to building upon this success and deepening our work with Tent to welcome even more refugees and migrants into the FEMSA workforce."

Safecor Health Adds Eddie Carrillo as VP of Quality and Regulatory

Retrieved on: 
Wednesday, January 31, 2024
FDA, VSCP, University, Therapy, Baxter, Quality, Hospital, Pharmaceutical industry

Mr. Carrillo joins the Safecor Health team after nearly three decades as a quality leader in the pharmaceutical manufacturing industry.

Key Points: 
  • Mr. Carrillo joins the Safecor Health team after nearly three decades as a quality leader in the pharmaceutical manufacturing industry.
  • "We are very excited to add Eddie's vast experience and insight to the Safecor team," said Steve Fischbach, CEO.
  • Mr. Carrillo joins Safecor Health with a focused background in pharmaceutical manufacturing, most recently serving as the Senior Director of Quality at Sage Therapeutics, ensuring FDA inspection readiness at various sites.
  • "I am excited to partner with the leadership team at Safecor Health and with VSCP," highlighted Mr. Carrillo.